ZA200600248B - Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof - Google Patents
Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof Download PDFInfo
- Publication number
- ZA200600248B ZA200600248B ZA200600248A ZA200600248A ZA200600248B ZA 200600248 B ZA200600248 B ZA 200600248B ZA 200600248 A ZA200600248 A ZA 200600248A ZA 200600248 A ZA200600248 A ZA 200600248A ZA 200600248 B ZA200600248 B ZA 200600248B
- Authority
- ZA
- South Africa
- Prior art keywords
- human
- protein
- codon
- vector
- sequence
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims description 24
- 108091007433 antigens Proteins 0.000 title claims description 24
- 102000036639 antigens Human genes 0.000 title claims description 24
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 title claims description 7
- 229940116978 human epidermal growth factor Drugs 0.000 title claims description 7
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 title claims description 7
- 108700005078 Synthetic Genes Proteins 0.000 title claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 159
- 102000004169 proteins and genes Human genes 0.000 claims description 120
- 239000013598 vector Substances 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 94
- 230000014509 gene expression Effects 0.000 claims description 90
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 80
- 239000013612 plasmid Substances 0.000 claims description 72
- 108091033319 polynucleotide Proteins 0.000 claims description 67
- 102000040430 polynucleotide Human genes 0.000 claims description 67
- 239000002157 polynucleotide Substances 0.000 claims description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 102000051957 human ERBB2 Human genes 0.000 claims description 47
- 108020004414 DNA Proteins 0.000 claims description 46
- 239000002773 nucleotide Substances 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 41
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 30
- 241000701161 unidentified adenovirus Species 0.000 claims description 28
- 229960005486 vaccine Drugs 0.000 claims description 28
- 210000005260 human cell Anatomy 0.000 claims description 25
- 230000003053 immunization Effects 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 19
- 101150029707 ERBB2 gene Proteins 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 238000011161 development Methods 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 230000009257 reactivity Effects 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 6
- 238000009566 cancer vaccine Methods 0.000 claims description 6
- 229940022399 cancer vaccine Drugs 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 5
- 101150054472 HER2 gene Proteins 0.000 claims description 5
- 230000024932 T cell mediated immunity Effects 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 229940021704 adenovirus vaccine Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 229940021995 DNA vaccine Drugs 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000028996 humoral immune response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000005030 transcription termination Effects 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 241001515965 unidentified phage Species 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims 93
- 108020004705 Codon Proteins 0.000 claims 48
- 241000699670 Mus sp. Species 0.000 claims 24
- 150000001413 amino acids Chemical group 0.000 claims 24
- 238000002649 immunization Methods 0.000 claims 21
- 235000001014 amino acid Nutrition 0.000 claims 19
- 229940024606 amino acid Drugs 0.000 claims 18
- 210000004988 splenocyte Anatomy 0.000 claims 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 12
- 241000699666 Mus <mouse, genus> Species 0.000 claims 11
- 230000003248 secreting effect Effects 0.000 claims 10
- 239000000047 product Substances 0.000 claims 9
- 238000011725 BALB/c mouse Methods 0.000 claims 8
- 241000701022 Cytomegalovirus Species 0.000 claims 8
- 238000004458 analytical method Methods 0.000 claims 8
- 108010006025 bovine growth hormone Proteins 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 8
- 238000002474 experimental method Methods 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 238000010212 intracellular staining Methods 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 229960001438 immunostimulant agent Drugs 0.000 claims 7
- 239000003022 immunostimulating agent Substances 0.000 claims 7
- 230000003308 immunostimulating effect Effects 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 230000004044 response Effects 0.000 claims 7
- 101150029662 E1 gene Proteins 0.000 claims 6
- 241000282560 Macaca mulatta Species 0.000 claims 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 6
- 229940065638 intron a Drugs 0.000 claims 6
- 210000004989 spleen cell Anatomy 0.000 claims 6
- 241000588724 Escherichia coli Species 0.000 claims 5
- 101000856426 Mus musculus Cullin-7 Proteins 0.000 claims 5
- 230000004075 alteration Effects 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 5
- 230000008488 polyadenylation Effects 0.000 claims 5
- 210000003314 quadriceps muscle Anatomy 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 210000000952 spleen Anatomy 0.000 claims 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 4
- 238000002965 ELISA Methods 0.000 claims 4
- 238000011510 Elispot assay Methods 0.000 claims 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 241000238631 Hexapoda Species 0.000 claims 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 4
- 241001135569 Human adenovirus 5 Species 0.000 claims 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 4
- 230000001594 aberrant effect Effects 0.000 claims 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000003098 myoblast Anatomy 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 238000010186 staining Methods 0.000 claims 4
- 238000001890 transfection Methods 0.000 claims 4
- 241000283707 Capra Species 0.000 claims 3
- 241000282693 Cercopithecidae Species 0.000 claims 3
- 108010062580 Concanavalin A Proteins 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 3
- 230000005867 T cell response Effects 0.000 claims 3
- 238000007792 addition Methods 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000010367 cloning Methods 0.000 claims 3
- 238000013461 design Methods 0.000 claims 3
- 230000002538 fungal effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 239000013600 plasmid vector Substances 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 108091008146 restriction endonucleases Proteins 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 101150028074 2 gene Proteins 0.000 claims 2
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 108700010070 Codon Usage Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 241000699660 Mus musculus Species 0.000 claims 2
- 238000012408 PCR amplification Methods 0.000 claims 2
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 2
- 238000002835 absorbance Methods 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 claims 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 239000013613 expression plasmid Substances 0.000 claims 2
- 238000000684 flow cytometry Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 230000009871 nonspecific binding Effects 0.000 claims 2
- 230000002246 oncogenic effect Effects 0.000 claims 2
- 238000005457 optimization Methods 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 238000004448 titration Methods 0.000 claims 2
- 238000011830 transgenic mouse model Methods 0.000 claims 2
- 238000013519 translation Methods 0.000 claims 2
- 230000014616 translation Effects 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- YKUPBWMOBLEEMC-UHFFFAOYSA-N (5-bromo-4-chloro-1H-indol-3-yl) phosphate 2H-tetrazol-1-ium Chemical compound C=1N=NN[NH+]=1.C=1N=NN[NH+]=1.C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 YKUPBWMOBLEEMC-UHFFFAOYSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- -1 293 cells Proteins 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000255789 Bombyx mori Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 108010084313 CD58 Antigens Proteins 0.000 claims 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 claims 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 108010067770 Endopeptidase K Proteins 0.000 claims 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- 101150031823 HSP70 gene Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 101100348738 Mus musculus Noc3l gene Proteins 0.000 claims 1
- 241001467460 Myxogastria Species 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims 1
- 239000012980 RPMI-1640 medium Substances 0.000 claims 1
- 101150039863 Rich gene Proteins 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 claims 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 108010006785 Taq Polymerase Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940027570 adenoviral vector vaccine Drugs 0.000 claims 1
- 238000005377 adsorption chromatography Methods 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000007975 buffered saline Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 230000004700 cellular uptake Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 101150052825 dnaK gene Proteins 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 239000012894 fetal calf serum Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229940047127 fiore Drugs 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229940042743 immune sera Drugs 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 231100000590 oncogenic Toxicity 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000001742 protein purification Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 238000010242 retro-orbital bleeding Methods 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000013207 serial dilution Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 230000007781 signaling event Effects 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000010561 standard procedure Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 230000005026 transcription initiation Effects 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 238000005199 ultracentrifugation Methods 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 150000003679 valine derivatives Chemical class 0.000 claims 1
- 238000003260 vortexing Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 claims 1
- 229960001600 xylazine Drugs 0.000 claims 1
- 230000010261 cell growth Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000011340 peptidyl-tyrosine autophosphorylation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48923703P | 2003-07-21 | 2003-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600248B true ZA200600248B (en) | 2007-03-28 |
Family
ID=34115329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600248A ZA200600248B (en) | 2003-07-21 | 2006-01-10 | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20070111957A1 (de) |
| EP (1) | EP1649020B1 (de) |
| JP (1) | JP4772674B2 (de) |
| KR (1) | KR101141507B1 (de) |
| CN (2) | CN101173282B (de) |
| AU (1) | AU2004261724B2 (de) |
| CA (1) | CA2532460C (de) |
| IL (1) | IL173208A (de) |
| IS (1) | IS8200A (de) |
| NO (1) | NO20060813L (de) |
| NZ (1) | NZ544543A (de) |
| RU (1) | RU2397249C2 (de) |
| WO (1) | WO2005012527A1 (de) |
| ZA (1) | ZA200600248B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539567A1 (de) | 2007-07-02 | 2019-09-18 | Etubics Corporation | Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen |
| GB2484058A (en) * | 2009-12-01 | 2012-04-04 | Uni Konstanz | Prostate cancer DNA vaccine |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| CN103555765B (zh) * | 2013-05-30 | 2015-01-07 | 中南大学湘雅医院 | 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用 |
| CA2945308C (en) | 2014-04-10 | 2023-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Transgene genetic tags and methods of use |
| EP3256140B1 (de) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Zusammensetzungen für ebola-virus-impfstoff |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| US11266726B2 (en) | 2015-10-30 | 2022-03-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of HER2-expressing solid tumors |
| AU2017375630B2 (en) | 2016-12-12 | 2023-12-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| WO2019038388A1 (en) | 2017-08-24 | 2019-02-28 | Bavarian Nordic A/S | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
| CN112941132B (zh) * | 2021-05-17 | 2021-07-23 | 烟台市华昕生物医药科技有限公司 | 一种利用大肠杆菌表达寡肽-1的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5837523A (en) * | 1994-05-05 | 1998-11-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| IT1276662B1 (it) * | 1995-04-04 | 1997-11-03 | Uni Degli Studi Camerino | Vaccini polinucleotidici |
| WO2000044899A1 (en) * | 1999-01-29 | 2000-08-03 | Corixa Corporation | Her-2/neu fusion proteins |
| CA2419533A1 (en) * | 2000-08-14 | 2002-02-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
| EP1320621A4 (de) | 2000-09-15 | 2005-11-23 | Merck & Co Inc | Verbesserte adenovirale vakzine der ersten generation zur expression codon-optimierten hiv1-gag, pol, nef und modifikationen(25.03.02) |
| CN1164330C (zh) * | 2001-07-19 | 2004-09-01 | 中国医学科学院基础医学研究所 | 一种重组复制缺陷型腺病毒载体狂犬病毒基因工程疫苗 |
| KR100555211B1 (ko) * | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신 |
| WO2004041065A2 (en) * | 2002-10-30 | 2004-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS |
| WO2004061105A1 (en) | 2003-01-03 | 2004-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Rhesus her2/neu, nucleotides encoding same, and uses thereof |
-
2004
- 2004-07-20 CN CN2007101679791A patent/CN101173282B/zh not_active Expired - Fee Related
- 2004-07-20 WO PCT/EP2004/008234 patent/WO2005012527A1/en active Application Filing
- 2004-07-20 EP EP04763424.1A patent/EP1649020B1/de active Active
- 2004-07-20 CA CA2532460A patent/CA2532460C/en not_active Expired - Fee Related
- 2004-07-20 CN CNB2004800209172A patent/CN100558894C/zh not_active Expired - Fee Related
- 2004-07-20 US US10/565,418 patent/US20070111957A1/en not_active Abandoned
- 2004-07-20 NZ NZ544543A patent/NZ544543A/en not_active IP Right Cessation
- 2004-07-20 KR KR1020067001426A patent/KR101141507B1/ko not_active IP Right Cessation
- 2004-07-20 JP JP2006520798A patent/JP4772674B2/ja not_active Expired - Fee Related
- 2004-07-20 AU AU2004261724A patent/AU2004261724B2/en not_active Ceased
- 2004-07-20 RU RU2006105195/13A patent/RU2397249C2/ru not_active IP Right Cessation
-
2005
- 2005-12-27 IS IS8200A patent/IS8200A/is unknown
-
2006
- 2006-01-10 ZA ZA200600248A patent/ZA200600248B/en unknown
- 2006-01-17 IL IL173208A patent/IL173208A/en not_active IP Right Cessation
- 2006-02-20 NO NO20060813A patent/NO20060813L/no not_active Application Discontinuation
-
2008
- 2008-11-14 US US12/291,886 patent/US7662586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL173208A0 (en) | 2006-06-11 |
| CN100558894C (zh) | 2009-11-11 |
| AU2004261724B2 (en) | 2010-06-17 |
| CA2532460C (en) | 2012-04-24 |
| US7662586B2 (en) | 2010-02-16 |
| EP1649020B1 (de) | 2017-01-11 |
| RU2397249C2 (ru) | 2010-08-20 |
| EP1649020A1 (de) | 2006-04-26 |
| US20090098604A1 (en) | 2009-04-16 |
| CA2532460A1 (en) | 2005-02-10 |
| KR101141507B1 (ko) | 2012-05-08 |
| WO2005012527A9 (en) | 2006-03-02 |
| CN101173282B (zh) | 2011-04-06 |
| JP2006527989A (ja) | 2006-12-14 |
| US20070111957A1 (en) | 2007-05-17 |
| IS8200A (is) | 2005-12-27 |
| KR20060052852A (ko) | 2006-05-19 |
| IL173208A (en) | 2014-06-30 |
| RU2006105195A (ru) | 2006-06-27 |
| CN1826409A (zh) | 2006-08-30 |
| JP4772674B2 (ja) | 2011-09-14 |
| CN101173282A (zh) | 2008-05-07 |
| NO20060813L (no) | 2006-03-20 |
| WO2005012527A1 (en) | 2005-02-10 |
| AU2004261724A1 (en) | 2005-02-10 |
| NZ544543A (en) | 2009-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7662586B2 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| US8188244B2 (en) | Carcinoembryonic antigen fusions and uses thereof | |
| US20070104685A1 (en) | Synthetic gene encoding human carcinoembryonic antigen and uses thereof | |
| WO2008012237A1 (en) | Multi-antigen construct and uses thereof | |
| US7282365B2 (en) | Rhesus HER2/neu, nucleotides encoding same, and uses thereof | |
| US20060286114A1 (en) | Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof | |
| ZA200606358B (en) | Carcinoembryonic antigen fusions and uses thereof | |
| US20060228335A1 (en) | Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof | |
| ZA200508013B (en) | Synthetic gene encoding human carcinoembryonic antigen and use thereof | |
| MXPA06009202A (en) | Carcinoembryonic antigen fusions proteins and uses thereof | |
| WO2004015098A2 (en) | Rhesus epithelial cell adhesion molecule, nucleic acid encoding the same, and uses thereof |